Corporate Responsibility

Sandoz Inc. A Novartis Division, is committed to supporting educational grants for Independent Medical Education (IME), Fellowships, Medical Sponsorships, Corporate Memberships, and other worthwhile initiatives to support a specific educational or professional development activity directed to medical healthcare professionals and the scientific community in order to improve patient health. In addition, Sandoz will support activities that address the needs of nonprofit 501(c)(3), 501(c)(4), and 501(c)(6) organizations, healthcare or healthcare related organizations and foundations efforts in educating and supporting patients, their family members, caregivers and the public and are consistent with the mission of Sandoz. Such programs aim to improve patient health and are fully compliant with all legal and regulatory guidelines and the ethical standards under which Sandoz conducts business.

Sandoz Position for Independent Medical Education

Providers can help to advance healthcare equity, address disparities in healthcare delivery for underrepresented and diverse populations, and create culturally sensitive content. Providers should consider implementing systems which positively influence the way in which education is delivered to ensure diversity and inclusion with respect to faculty selection (ensuring diversity in faculty selection), intended learners or target audience (planning for diversity of the intended audience and content), and education plan (ensuring that the plan is inclusive, culturally sensitive, and that all diverse groups’ data are included).

The Sandoz Office of Grants and Education (SOGE) will review all requests received for Professional Independent Medical Education Grants, Patient Advocacy Organization Grants, Medical Sponsorships and Corporate Memberships that may cover the following therapeutic areas of interest:

•           General Biosimilar Education

•           Immunology

•           Endocrinology

•           Oncology

For more information and to submit a grant application, please access our new Grants, External studies and Managed access System (GEMS) platform at: Sandoz Office of Grants and Education

Guidance on using the Grants Submission portal is available here: Grants Submission Guide

Guidance on using the Sponsorships/Memberships portal is available here: Sponsorships/Memberships Submission Guide

Please take the time to consider how your educational program fits within the therapeutic areas of interest mentioned above and the established regulations, laws and guidelines and that your request is submitted at least 60 calendar days prior to the start of the event to allow adequate time for processing.

While many more requests are received than can be funded, we regret that we cannot accommodate every request. However, your request will receive a fair review once all documentation is submitted.

Contact Information

E-mail: [email protected]

Mail:     Sandoz Office of Grants and Education, 100 College Rd West, Princeton NJ 08540

For additional questions, please refer to this FAQ 

What constitutes Managed Access at Sandoz?

There are instances where a patient has a serious or life-threatening disease or condition, for which all currently available treatment options have been exhausted and enrollment into a clinical trial is not possible. In these cases, the treating physician can request an investigational or pre-approval product prior to regulatory approval, provided it is allowed by the applicable local laws. Within Sandoz, A Novartis Division, we refer to such provision of investigational or pre-approval products as “Managed Access.”

The Sandoz “Managed Access” terminology covers all locally defined pre-approval access mechanisms and programs such as “Compassionate Use”, “Expanded Access”, “Named Patient Supply”, “Special Access Schemes/Programs”, “Authorizations temporaires d’utilisation (ATU)” and others.

Sandoz “Managed Access” addresses this need by making certain investigational or unapproved treatments available to eligible patients.

Novartis Position on Pre-Approval Access to Novartis Products through Novartis Managed Access Programs (PDF 0.2 MB)

Who is eligible for Sandoz Managed Access programs?

Sandoz considers granting managed access to investigational or pre-approval products when all of the following criteria are met:

• The patient to be treated has a serious or life-threatening disease or condition, and no comparable or satisfactory alternative therapy is available to monitor or treat the disease or condition;
• The patient is ineligible for enrolment into or unable to access ongoing clinical trials;
• The patient meets any other important medical criteria established by the medical experts working on the product development program;
• Sufficient data exists to believe the potential benefit of treatment outweighs the potential risk in the context of the disease or condition to be treated;
• Sandoz has an adequate supply of the investigational product and providing the investigational product will not interfere with ongoing clinical trial(s) or with the overall development program;
• Such access provision is allowed as per local laws and regulations.
• Outside these programs, individual patient requests can be submitted for other compounds provided the Managed Access criteria are fulfilled.

How do I submit a request for Managed Access?

• A request must be submitted by the treating physician on behalf of the patient.

All requests can be submitted via our GEMS (Grants, External Trials and Managed Access System portal by clicking: Submit a Managed Access request

Guidance on using the portal: Novartis GEMS Portal External User Guide (PDF 0.1 MB)

How are requests evaluated?

Please note that your request will be assessed in consideration of applicable local laws and regulations. Each request will be acknowledged immediately, and reviewed carefully and fairly by the appropriate Sandoz medical lead with every effort made to provide a response promptly once all the necessary information has been submitted.

In addition, since 2017 Novartis has collaborated with an external Independent Bioethics Advisory Committee (IBAC), which provides analysis and recommendations on Novartis guidelines and policies for the ethical conduct of clinical research, and on selected ethical challenges, which may arise in clinical trials, development programs and managed access programs. The IBAC is comprised of bioethicists, clinicians, healthcare practitioners, patient advocates and other domain knowledge experts appropriate to the problem at hand.